Skip to content

Effects of non-surgical periodontal therapy on nutritional and inflammatory measurements among patients with end-stage renal disease: a randomized controlled trial of renal injury and periodontitis

Effects of non-surgical periodontal therapy on nutritional and inflammatory measurements among patients with end-stage renal disease: a randomized controlled trial of renal injury and periodontitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026814
Enrollment
Unknown
Registered
2019-10-23
Start date
2020-01-01
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis and end-stage renal disease

Interventions

experimental group:immediate non-surgical periodontal treatment
control group:delayed non-surgical periodontal treatment

Sponsors

The Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The age is between 18 and 80 years; (2) GFR < 15ml/ (min.1.73m2) and undergoing peritoneal dialysis or hemodialysis; (3) Moderate and severe periodontitis according to CDC/AAP criteria; (4) At least 10 natural teeth; (5) Not experience any periodontal treatments within 6 months before our trial.

Exclusion criteria

Exclusion criteria: (1) Immunosuppressants or antibiotics use more than 7 days within one month prior to recruitment; (2) During pregnancy, lactation or planning to become pregnant during the study period (3) Severe complications (such as metastatic cancer) and dementia that may affect life expectancy within 1 year. (4) Serious oral diseases that interfere with periodontal treatment, such as acute pulpitis. (5) Some contraindications of dental treatment according to clinicians'judgement. (6) Systemic or obvious local signs of infection / inflammation (PCT> 2ng/ml). (7) Abnormal liver function (AST/ALT > 3 times the normal upper limit).

Design outcomes

Primary

MeasureTime frame
hepcidin;

Secondary

MeasureTime frame
25-hydroxyvitamin D;ferritin;cholesterol;serum albumin;hs C-reactive protein;procalcitonin;CD14;MMP-9;IL-1ß;IL-6;TNFa;????;LPS;hemoglobin;

Countries

China

Contacts

Public ContactHaixia Lu

Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

ritalu0225@hotmail.com+86 18019790065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026